a commercial-stage company, which focuses on rare diseases that transform real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies
Industry MedicalSpecialties
This is a Bullish indicator signaling CNTGF's price could rise from here. Traders may explore going long the stock or buying call options. A.I. dvisor identified 52 similar cases where CNTGF's MACD histogram became positive, and of them led to successful outcomes. Odds of Success:
CNTGF saw its Momentum Indicator move above the 0 level on April 06, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 110 similar instances where the indicator turned positive. In of the 110 cases, the stock moved higher in the following days. The odds of a move higher are at .
The Moving Average Convergence Divergence (MACD) for CNTGF just turned positive on April 01, 2026. Looking at past instances where CNTGF's MACD turned positive, the stock continued to rise in of 52 cases over the following month. The odds of a continued upward trend are .
CNTGF moved above its 50-day moving average on March 25, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for CNTGF crossed bullishly above the 50-day moving average on March 17, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
The 10-day RSI Indicator for CNTGF moved out of overbought territory on March 18, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 18 similar instances where the indicator moved out of overbought territory. In of the 18 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 10 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (12.561). P/E Ratio (0.000) is within average values for comparable stocks, (106.947). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.397). CNTGF has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.017). P/S Ratio (0.053) is also within normal values, averaging (16.845).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CNTGF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CNTGF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.